low dose semaglutide for inflammation The NLRP3 inhibitor NT‐0796 enhances and sustains GLP‐1R agonist‐mediated weight loss in a murine diet‐induced obesity model - Thornton - 2025 - Obesity Effects of once-weekly semaglutide 2.4

YAP1 mediated the upregulation of ACSL4 through TEA domain transcription factor 1 (Tead1)/ TEA domain transcription factor 4 (Tead4)-related Hippo signaling, thus increasing LPO levels and causing ferroptosis in skeletal muscle cells (Yang et al., 2020

What GLP-1 medications do you prescribe

cGAS-STING pathway as a potential trigger of immunosenescence and inflammaging

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications primarily prescribed for type 2 diabetes management and, more recently, for chronic weight management

Administering a GLP-1 agonist affects multiple organs simultaneously, explaining secondary benefits like reduced appetite, cardiovascular improvements, and kidney protection

While rare, some individuals may experience mild gastrointestinal discomfort